* Note: Prices are in Million (M) USD.
Description:
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in Cambridge, Massachusetts, that is pioneering solutions for the urgent challenge of multidrug-resistant (MDR) bacterial infections and rare diseases. With a strong emphasis on innovation, Spero is advancing a robust pipeline of novel therapeutics designed to improve patient outcomes in areas with significant unmet medical needs. The company's strategic focus on combating resistance in bacterial pathogens positions it as a key player in addressing critical healthcare challenges in the United States and beyond.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $49 M
Debt : $2 M
EBITDA : $-45 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Biotechnology
Biotechnology detected → treating as non-Technology. 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 3.27
Since Forward PE Ratio is less than 15, 5 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 10 overlapping fiscal years (max 20).Average Free Cash Flow: $-45 M
Average Revenue: $22 M
Revenue Converted To Free Cash Flow (%): -201.1%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $48 M
Revenue 5 Years Ago (2019-12-31): $5 M
Total Growth over 5 Years: 911.7%
5-Year Revenue CAGR (Historical): 58.9%
Forward 5-Year CAGR (Tapered): 29.4%
Since historical Revenue CAGR is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $54 M
Share Count 5 Years Ago (2020-12-31): $22 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $0.67
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.67
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 10 valid ROE years (max 20).Average ROE: -595.1%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $2.19
52-Week Low: $0.51
Threshold Price (15% Above 52-Week Low): $0.58
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $125 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 0.5% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
No positive free cash flow found (TTM or annual) to compute Owners' Earnings per share.
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 14 points to above Spero Therapeutics Inc (SPRO) stock.
Heads up: One or more P/E inputs look exaggerated and may skew the blend.
• Growth Based PE 50.00 (>2× median)
Further research is recommended; please use your own due diligence.
In such cases, multiplying earnings by the long-run average P/E typically gives a closer, more reliable fair value.
Fair Value PE
12, Industry Based PE
15, Growth Based PE
50, Risk-Free Anchored PE (25% MoS)
18.12. Based on these 4 values, average assigned is
23.78. Value-Trades has assined P/E value
23.78. An average (Current Year EPS + Next Year EPS) earning per share is
$0.67.
Note: Final fair value is the lesser of the blended PE-based fair value and the simple average PE × EPS fair value.Fair value using multiple P/Es (blended): $15.93 (PE 23.78 × EPS $0.67)
Fair value using simple average PE × EPS: $15.93 (PE 23.78 × EPS $0.67)
Lesser of these two: $15.93
So the Final Fair Value is: $15.93
Understanding the Value-Trades P/E Blend (click to expand)
▾
What goes into the blended P/E?
- 20-Year Avg P/E — Long-run market baseline; conservative anchor.
- Fair Value P/E — Score-based (cash, debt, sector, etc.).
- Industry P/E — Peer group norm.
- Growth-Based P/E — Uses tapered growth rates, floored at 15.
- RCFC-Based P/E — Maps cash conversion efficiency.
- ROE-Based P/E — Higher ROE supports higher multiples.
- Risk-Free Anchored P/E — Macro floor tied to 10y yield w/ MoS.
How it works
- Extreme values are clamped/filtered (IQR method).
- Anchors (20y avg, RCFC/ROE, risk-free) are always kept if valid.
- Final fair value = min(Blended PE × EPS, Avg PE × EPS).
P/E Reference Summary
Using EPS: $0.67
| Source |
P/E Ratio |
Implied Fair Value |
| Market (1 Yr Ago) | 2.83 | $1.90 |
| Value-Trades Assigned | 23.78 | $15.93 |
